Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Ding, Heng ^a   Tsai, Cheguo ^a   Gutiérrez, Ramona Alikiiteaga ^b   Zhou, Fan ^a   Buchy, Philippe ^b   Deubel, Vincent ^b   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; DNA VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LD 50; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; TREATMENT OUTCOME; VACCINATION;

AVES; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE;

EID: 79551516478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016563     Document Type: Article

References (50)

1. Chen H, Smith GJ, Li KS, Wang J, Fan XH, et al. (2006) Establishment ofmultiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 103: 2845-2850.
2. Webster RG, Peiris M, Chen H, Guan Y (2006) H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 12: 3-8.
3. World Health Organization Global Influenza Program Surveillance Network. (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11: 1515-1521.
4. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. Available:http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_07_05/en/index.html
5. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. (2008) Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 358: 261-273.
6. Smith GJD, Fan XH, Wang J, Li KS, Qin K, et al. (2006) Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A 45: 16936-16941.
7. Gutierrez RA, Naughtin MJ, Horn SV, San S, Buchy P (2009) A(H5N1) virus evolution in South East Asia. Viruses 1: 335-361.
8. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-1664.
9. Lin J, Zhang J, Dong X, Fang H, Chen J, et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991-997.
10. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, et al. (2006) Crossprotective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24: 6588-6593.
11. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD (1999) ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17: 1355-1358.
12. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-1351.
13. Subbarao K, Joseph T (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7: 267-278.
14. Song H, Nieto GR, Perez DR (2007) A new generation of modified liveattenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol 81: 9238-9248.
15. Horimoto T, Kawaoka Y (2006) Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 12: 506-514.
16. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirusbased immunization. J Virol 80: 1959-1964.
17. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
18. Bublot M, Pritchard N, Cruz JS, Mickle TR, Selleck P, et al. (2007) Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge. Avian Dis 51(1 Suppl): 498-500.
19. Bukreyev A, Huang Z, Yang L, Elankumaran S, Claire M, et al. (2005) Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79: 13275-13284.
20. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3: e1501.
21. Quan FS, Huang C, Compans RW, Kang SM (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81: 3514-3524.
22. Crevar CJ, Ross TM (2008) Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 5: 131.
23. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26: 5393-5399.
24. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, et al. (2009) Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. pp e4667.
25. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, et al. (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 83: 5726-5734.
26. Szécsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, et al. (2006) Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 3: 70.
27. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM (2003) Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 308: 270-278.
28. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8: 796-801.
29. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, et al. (2008) Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/ Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197: 1643-1652.
30. Sharpe M, Lynch D, Topham S, Major D, Wood J, et al. (2007) Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25: 6392-6398.
31. Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, et al. (2008) Multivalent HA DNA Vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 3: e2432.
32. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, et al. (2008) A consensushemagglutinin- based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 105: 13538-13543.
33. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, et al. (2010) Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28: 2565-2572.
34. Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG (2005) Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 102: 12915-12920.
35. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, et al. (2007) Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317: 825-828.
36. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357: 1450-1451.
37. Buchy P, Mardy S, Vong S, Toyoda T, Aubin JT, et al. (2007) Influenza A/ H5N1 virus infection in humans in Cambodia. J Clin Virol 39: 164-168.
38. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
39. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.
40. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
41. Tsai C, Caillet C, Hu H, Zhou F, Ding H, et al. (2009) Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27: 6777-6790.
42. Ramshaw IA, Ramsay AJ (2000) The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21: 163-165.
43. Ikeno D, Kimachi K, Kudo Y, Goto S, Itamura S, et al. (2009) A prime-boost vaccination of mice with heterologous H5N1 strains. Vaccine 27: 3121-3125.
44. Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, et al. (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: coldadapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26: 2062-2072.
45. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, et al. (2008) Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-3633.
46. Steensels M, Bublot M, Van Borm S, De Vriese J, Lambrecht B, et al. (2009) Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine 27: 646-654.
47. Pan Z, Zhang X, Geng S, Fang Q, You M, et al. (2010) Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus. Clin Vaccine Immunol 17: 518-523.
48. Sabarth N, Howard MK, Savidis-Dacho H, van Maurik A, Barrett PN, et al. (2010) Comparison of single, homologous prime-boost and heterologous primeboost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 28: 650-656.
49. Gonzalez-Fernandez A, Milstein C (1998) Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation. Immunology 93: 149-153.
50. Bot A, Antohi S, Bona C (1997) Immune response of neonates elicited by somatic transgene vaccination with naked DNA. Front Biosci 2: d173-188.